Additional Restriction Spectrum Imaging MRIs to Improve Early Detection of Prostate Cancer, IMAGINED Trial
This phase II trial tests whether additional restriction spectrum imaging (RSI) magnetic resonance imaging (MRIs) improves the early detection of prostate cancer. Prostate cancer is one of the most common cancers and a leading cause of death among men in America. However, prostate cancer detection can be imprecise. Improving early prostate cancer detection through the use of non-invasive imaging, or MRIs, at time of a prostate biopsy, can help identify prostate cancer tumors that need treatment. An MRI-guided prostate biopsy is a procedure that combines the pictures from an MRI scan and an ultrasound to create a detailed three dimensional (3-D) image of the prostate. This procedure makes it easier to see an abnormal area of tissue in order to guide the biopsy needle into any abnormal area. Because MRI imaging software and sequencing equipment can vary, this study proposes to compare multiple MRIs to see if additional imaging can improve the detection of any abnormal area of tissue at time of a MRI-guided prostate biopsy. Two MRIs performed for purposes of this research will be combined with, and compared to, the clinical MRI scan done as part of routine standard of care at time of routine prostate biopsy. The information gained from this trial may help researchers learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.